Showing 661-670 of 8173 results for "".
Warts and All: Treating and Assessing Warts During COVID-19
https://practicaldermatology.com/series/dermatology-dispatches/warts-and-all-treating-and-assessing-warts-during-covid-19/19774/Many warts can be safely treated at home during the COVID-19 pandemic, but new onset warts that are changing colors or bleeding could be squamous cell carcinomas and may require evaluation, explains Neal Bhatia, MD.First Cell-Based Gene Therapy for RDEB
https://practicaldermatology.com/series/dermwire-tv/first-cell-based-gene-therapy-for-rdeb/35742/In this week's DermwireTV, the FDA approves the first cell-based gene therapy for recessive dystophic epidermolysis bullosa (RDEB); a new acne scar treatment using focal point technology is cleared in the US; and in our “Updates on Skin Cancer” feature, we hear about the advantages of 40-GEP testingDermWire TV Extra: Dr. Ruiz on GEP Testing for SCC
https://practicaldermatology.com/topics/skin-of-color/dermwire-tv-extra-dr-ruiz-gep-testing-scc/29497/Emily Ruiz, MD, MPH, FAAD, a Mohs surgeon at Brigham and Women's Hospital and cutaneous oncologist at Dana-Farber Cancer Institute, discusses her recent Future Oncology article, "Predicting adjuvant radiation therapy benefit in cutaneous squamous cell carcinoma with the 40-gene expression profile."Noah Worcester 2024: Dr. Gold on Toxins
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-gold-toxins/24583/Noah Worcester 2024: Dr. Gold on ToxinsEmbracing Photodynamic Therapy (PDT) in Your Practice
https://practicaldermatology.com/series/pdt-in-practice/embracing-photodynamic-therapy-pdt-in-your-practice/20209/Dr. Neal Bhatia, Chief Medical Editor of Practical Dermatology, provides updates in photodynamic therapy (PDT) and how to incorporate its techniques and technologies into everyday practice. Dr. Bhatia also provides some practical advice on using the therapy and on protecting yourself and your patienTrends in the Medical Aesthetic Market
https://practicaldermatology.com/series/c-suite-chats/trends-in-the-medical-aesthetic-market/24560/Ethan Min, CEO of Benev, discusses trends in the medical aesthetic market, including the potential impact that Glucagon-like peptide-1 (GLP-1) for weight loss will have on the aesthetics industry.Tolerability of JAK Inhibitors Used in Dermatology
https://practicaldermatology.com/series/jak-inhibitors-in-practice/tolerability-of-jak-inhibitors-used-in-dermatology/20126/Although safety and tolerability are often intertwined, they are distinct considerations. Topical and oral JAKs used in dermatology today seem to offer good tolerability. Adelaide A. Hebert, MD and Matthew Zirwas, MD discuss potential side effects, management, and monitoring in pediatric and adult pDermWireTV: Clinical Support Tech Data; Dupixent, Stelara Updates; Rihanna Launches Fenty Skin
https://practicaldermatology.com/topics/psoriasis/dermwiretv-clinical-support-tech-data-dupixent-stelara-updates-rihanna-launches-fenty-skin/19835/A feasibility study in collaboration between LEO Innovation Lab, VisualDX, and the German Association of Dermatological Prevention supports technology to assist in diagnosis of skin conditions. Leo Pharma’s investigational JAK inhibitor delgocitinib cream is Fast Tracked by the FDA for the potentiaAntibiotics and Cosmetic Trends; Seysara Launches
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-antibiotics-and-cosmetics-trends-seysara-launches/19532/Dermatologists are prescribing fewer antibiotics to manage acne and rosacea. But, the use of antibiotics after surgical procedures is on the rise. More than one third of American adults are considering a cosmetic treatment in 2019, results of a RealSelf survey show. Seysara (sarecycline), a novel teThe Emergence of Targeted Therapies for Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/the-emergence-of-targeted-therapies-for-prurigo-nodularis/48775/Christopher Bunick, MD, FAAD, discusses the importance of acknowledging prurigo nodularis as a distinct disease with its own molecular and transcriptomic features distinguishing it from atopic dermatitis, and how targeting the IL-31 receptor can change the game.